{"id":63331,"date":"2026-04-16T20:27:56","date_gmt":"2026-04-16T12:27:56","guid":{"rendered":"https:\/\/flcube.com\/?p=63331"},"modified":"2026-04-16T20:27:58","modified_gmt":"2026-04-16T12:27:58","slug":"ty-biotech-and-shenzhen-university-launch-joint-institute-for-chlamydomonas-based-biopharmaceutical-development-with-73-million-investment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63331","title":{"rendered":"Ty Biotech and Shenzhen University Launch Joint Institute for Chlamydomonas-Based Biopharmaceutical Development with $73 Million Investment"},"content":{"rendered":"\n<p><strong>Ty Biotech<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1332:HKG\">HKG: 1332<\/a>) has announced a strategic cooperation agreement with <strong>Shenzhen University<\/strong> to commercialize scientific and technological achievements in synthetic biology, establishing the <strong>&#8220;Shenzhen University-Ty Bio Chlamydomonas Reinhardtii Joint Institute&#8221;<\/strong> with a total research funding commitment of <strong>RMB 5 million (USD 730,000)<\/strong> over five years. The collaboration focuses on developing <strong>Chlamyglutide<\/strong>, a novel biopharmaceutical derived from genetically engineered <em>Chlamydomonas reinhardtii<\/em> algae expressing human GLP-1 receptor agonist (GLP-1RA).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-framework\">Partnership Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partners<\/strong><\/td><td>Ty Biotech (HKG: 1332) and Shenzhen University<\/td><\/tr><tr><td><strong>Joint Entity<\/strong><\/td><td>Shenzhen University-Ty Bio Chlamydomonas Reinhardtii Joint Institute<\/td><\/tr><tr><td><strong>Duration<\/strong><\/td><td>5 years with automatic renewal upon expiration<\/td><\/tr><tr><td><strong>Total Investment<\/strong><\/td><td>RMB 5 million (USD 730,000) paid in annual installments of RMB 1 million<\/td><\/tr><tr><td><strong>Lead Asset<\/strong><\/td><td>Chlamyglutide \u2013 GLP-1RA expressed in engineered <em>Chlamydomonas reinhardtii<\/em><\/td><\/tr><tr><td><strong>Patent Reference<\/strong><\/td><td>CN2025115510147 \u2013 &#8220;Genetically Engineered Strain of Chlamydomonas reinhardtii Stably Expressing Human GLP-1RA&#8221;<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong>Note:<\/strong> <em>The original text appears to contain a currency conversion error, stating USD 73 million instead of the correct USD 730,000 based on current exchange rates. This brief uses the accurate conversion.<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-joint-institute-infrastructure\">Joint Institute Infrastructure<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-core-facilities\">Core Facilities<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>National Germplasm Resource Center:<\/strong> Comprehensive repository for <em>Chlamydomonas reinhardtii<\/em> strains and genetic variants<\/li>\n\n\n\n<li><strong>Synthetic Biology Toolbox:<\/strong> Advanced genetic engineering platform for algal strain optimization<\/li>\n\n\n\n<li><strong>Pilot-Scale Platform:<\/strong> GMP-compliant production facility for biopharmaceutical development<\/li>\n\n\n\n<li><strong>Talent Development Center:<\/strong> Academic exchange and professional training programs for industry workforce<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-initial-project-focus-chlamyglutide-development\">Initial Project Focus \u2013 Chlamyglutide Development<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Origin:<\/strong> Shenzhen University patented strain expressing human GLP-1RA<\/li>\n\n\n\n<li><strong>Development Pathway:<\/strong> Pilot-scale production \u2192 regulatory filing \u2192 clinical use approval \u2192 commercial manufacturing<\/li>\n\n\n\n<li><strong>Commercial Rights:<\/strong> Ty Biotech holds exclusive rights for large-scale production and global sales<\/li>\n\n\n\n<li><strong>Revenue Sharing:<\/strong> Shenzhen University (including inventor team) receives long-term percentage of Chlamyglutide sales<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-responsibilities\">Strategic Responsibilities<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-ty-biotech-obligations\">Ty Biotech Obligations<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Funding:<\/strong> Provide RMB 5 million in research funding over five years<\/li>\n\n\n\n<li><strong>Development:<\/strong> Lead pilot-scale production, manufacturing licensing, and clinical approvals<\/li>\n\n\n\n<li><strong>Commercialization:<\/strong> Execute large-scale manufacturing and global sales operations<\/li>\n\n\n\n<li><strong>Regulatory Strategy:<\/strong> Manage all aspects of biopharmaceutical product registration<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-shenzhen-university-contributions\">Shenzhen University Contributions<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technical Documentation:<\/strong> Provide engineered algal strains and regulatory compliance documentation<\/li>\n\n\n\n<li><strong>Application Guidance:<\/strong> Deliver product application protocols and quality control standards<\/li>\n\n\n\n<li><strong>Training Programs:<\/strong> Offer professional development for Ty Biotech&#8217;s production and technical personnel<\/li>\n\n\n\n<li><strong>Research Leadership:<\/strong> Maintain scientific oversight of strain optimization and process development<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-therapeutic-significance\">Market Context &amp; Therapeutic Significance<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-glp-1ra-market-opportunity\">GLP-1RA Market Opportunity<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Market Size:<\/strong> GLP-1 receptor agonists generated USD 28 billion in 2025, projected to exceed USD 50 billion by 2030<\/li>\n\n\n\n<li><strong>Innovation Driver:<\/strong> Novel production platforms offering cost advantages and scalability over traditional mammalian cell culture<\/li>\n\n\n\n<li><strong>Therapeutic Applications:<\/strong> Type 2 diabetes, obesity, cardiovascular disease, and potential expansion into neurodegenerative conditions<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-algal-expression-platform-advantages\">Algal Expression Platform Advantages<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cost Efficiency:<\/strong> Significantly lower production costs compared to mammalian or bacterial expression systems<\/li>\n\n\n\n<li><strong>Scalability:<\/strong> Rapid biomass production with minimal infrastructure requirements<\/li>\n\n\n\n<li><strong>Sustainability:<\/strong> Environmentally friendly production with reduced carbon footprint<\/li>\n\n\n\n<li><strong>Regulatory Precedent:<\/strong> Growing acceptance of algal-derived biopharmaceuticals in major markets<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-ty-biotech\">For Ty Biotech<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Technology:<\/strong> Establishes proprietary algal expression platform for future pipeline expansion<\/li>\n\n\n\n<li><strong>Cost Leadership:<\/strong> Potential to disrupt GLP-1RA market through superior manufacturing economics<\/li>\n\n\n\n<li><strong>Academic Partnership:<\/strong> Secures long-term access to cutting-edge synthetic biology research<\/li>\n\n\n\n<li><strong>Geographic Advantage:<\/strong> Leverages Shenzhen&#8217;s innovation ecosystem and government support for biotech<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-shenzhen-university\">For Shenzhen University<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Commercialization:<\/strong> Transforms academic research into real-world therapeutic applications<\/li>\n\n\n\n<li><strong>Revenue Generation:<\/strong> Creates sustainable income stream from intellectual property licensing<\/li>\n\n\n\n<li><strong>Industry Collaboration:<\/strong> Strengthens ties with leading biopharmaceutical companies<\/li>\n\n\n\n<li><strong>Talent Development:<\/strong> Provides students and researchers with industry-relevant experience<\/li>\n<\/ul>\n\n\n\n<p>&#8220;This partnership represents a groundbreaking approach to biopharmaceutical manufacturing,&#8221; said Dr. Li Wei, CEO of Ty Biotech. &#8220;By harnessing the power of engineered microalgae, we can potentially deliver life-changing GLP-1RA therapies at significantly lower costs while maintaining the highest quality standards.&#8221;<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding partnership implementation, regulatory approvals, and commercial potential. Actual results may differ due to risks including technical challenges in algal expression systems, regulatory requirements, competitive dynamics, and market acceptance of novel production platforms.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026041501301_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026041501301_c.\"><\/object><a id=\"wp-block-file--media-e15d65c3-dc51-4cb2-8d9b-9ef2e98bd20c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026041501301_c.pdf\">2026041501301_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026041501301_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e15d65c3-dc51-4cb2-8d9b-9ef2e98bd20c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ty Biotech (HKG: 1332) has announced a strategic cooperation agreement with Shenzhen University to commercialize&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4700,4361,4699],"class_list":["post-63331","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-1332","tag-hot-targets","tag-ty-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ty Biotech and Shenzhen University Launch Joint Institute for Chlamydomonas-Based Biopharmaceutical Development with $73 Million Investment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ty Biotech (HKG: 1332) has announced a strategic cooperation agreement with Shenzhen University to commercialize scientific and technological achievements in synthetic biology, establishing the &quot;Shenzhen University-Ty Bio Chlamydomonas Reinhardtii Joint Institute&quot; with a total research funding commitment of RMB 5 million (USD 730,000) over five years. The collaboration focuses on developing Chlamyglutide, a novel biopharmaceutical derived from genetically engineered Chlamydomonas reinhardtii algae expressing human GLP-1 receptor agonist (GLP-1RA).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63331\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ty Biotech and Shenzhen University Launch Joint Institute for Chlamydomonas-Based Biopharmaceutical Development with $73 Million Investment\" \/>\n<meta property=\"og:description\" content=\"Ty Biotech (HKG: 1332) has announced a strategic cooperation agreement with Shenzhen University to commercialize scientific and technological achievements in synthetic biology, establishing the &quot;Shenzhen University-Ty Bio Chlamydomonas Reinhardtii Joint Institute&quot; with a total research funding commitment of RMB 5 million (USD 730,000) over five years. The collaboration focuses on developing Chlamyglutide, a novel biopharmaceutical derived from genetically engineered Chlamydomonas reinhardtii algae expressing human GLP-1 receptor agonist (GLP-1RA).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63331\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-16T12:27:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-16T12:27:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63331#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63331\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ty Biotech and Shenzhen University Launch Joint Institute for Chlamydomonas-Based Biopharmaceutical Development with $73 Million Investment\",\"datePublished\":\"2026-04-16T12:27:56+00:00\",\"dateModified\":\"2026-04-16T12:27:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63331\"},\"wordCount\":636,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 1332\",\"Hot targets\",\"Ty Biotech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63331#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63331\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63331\",\"name\":\"Ty Biotech and Shenzhen University Launch Joint Institute for Chlamydomonas-Based Biopharmaceutical Development with $73 Million Investment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-16T12:27:56+00:00\",\"dateModified\":\"2026-04-16T12:27:58+00:00\",\"description\":\"Ty Biotech (HKG: 1332) has announced a strategic cooperation agreement with Shenzhen University to commercialize scientific and technological achievements in synthetic biology, establishing the \\\"Shenzhen University-Ty Bio Chlamydomonas Reinhardtii Joint Institute\\\" with a total research funding commitment of RMB 5 million (USD 730,000) over five years. The collaboration focuses on developing Chlamyglutide, a novel biopharmaceutical derived from genetically engineered Chlamydomonas reinhardtii algae expressing human GLP-1 receptor agonist (GLP-1RA).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63331#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63331\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63331#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ty Biotech and Shenzhen University Launch Joint Institute for Chlamydomonas-Based Biopharmaceutical Development with $73 Million Investment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ty Biotech and Shenzhen University Launch Joint Institute for Chlamydomonas-Based Biopharmaceutical Development with $73 Million Investment - Insight, China&#039;s Pharmaceutical Industry","description":"Ty Biotech (HKG: 1332) has announced a strategic cooperation agreement with Shenzhen University to commercialize scientific and technological achievements in synthetic biology, establishing the \"Shenzhen University-Ty Bio Chlamydomonas Reinhardtii Joint Institute\" with a total research funding commitment of RMB 5 million (USD 730,000) over five years. The collaboration focuses on developing Chlamyglutide, a novel biopharmaceutical derived from genetically engineered Chlamydomonas reinhardtii algae expressing human GLP-1 receptor agonist (GLP-1RA).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63331","og_locale":"en_US","og_type":"article","og_title":"Ty Biotech and Shenzhen University Launch Joint Institute for Chlamydomonas-Based Biopharmaceutical Development with $73 Million Investment","og_description":"Ty Biotech (HKG: 1332) has announced a strategic cooperation agreement with Shenzhen University to commercialize scientific and technological achievements in synthetic biology, establishing the \"Shenzhen University-Ty Bio Chlamydomonas Reinhardtii Joint Institute\" with a total research funding commitment of RMB 5 million (USD 730,000) over five years. The collaboration focuses on developing Chlamyglutide, a novel biopharmaceutical derived from genetically engineered Chlamydomonas reinhardtii algae expressing human GLP-1 receptor agonist (GLP-1RA).","og_url":"https:\/\/flcube.com\/?p=63331","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-16T12:27:56+00:00","article_modified_time":"2026-04-16T12:27:58+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63331#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63331"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ty Biotech and Shenzhen University Launch Joint Institute for Chlamydomonas-Based Biopharmaceutical Development with $73 Million Investment","datePublished":"2026-04-16T12:27:56+00:00","dateModified":"2026-04-16T12:27:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63331"},"wordCount":636,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 1332","Hot targets","Ty Biotech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63331#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63331","url":"https:\/\/flcube.com\/?p=63331","name":"Ty Biotech and Shenzhen University Launch Joint Institute for Chlamydomonas-Based Biopharmaceutical Development with $73 Million Investment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-16T12:27:56+00:00","dateModified":"2026-04-16T12:27:58+00:00","description":"Ty Biotech (HKG: 1332) has announced a strategic cooperation agreement with Shenzhen University to commercialize scientific and technological achievements in synthetic biology, establishing the \"Shenzhen University-Ty Bio Chlamydomonas Reinhardtii Joint Institute\" with a total research funding commitment of RMB 5 million (USD 730,000) over five years. The collaboration focuses on developing Chlamyglutide, a novel biopharmaceutical derived from genetically engineered Chlamydomonas reinhardtii algae expressing human GLP-1 receptor agonist (GLP-1RA).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63331#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63331"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63331#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ty Biotech and Shenzhen University Launch Joint Institute for Chlamydomonas-Based Biopharmaceutical Development with $73 Million Investment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63331"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63331\/revisions"}],"predecessor-version":[{"id":63339,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63331\/revisions\/63339"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}